INVA vs MRK
INVA: Innoviva is a diversified pharmaceutical holding company managing a portfolio of respiratory royalty assets and specialty medicine operations. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | INVA | MRK | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $21.28 | $148.30 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-20) | $1.5B | $365.9B | |
| P/E as of 2026-10-20 | 4.94 (earnings are mostly non-operating: 61% of trailing pre-tax income, to 2026-06-30) | 118.64 | |
| Net margin FY2025, SEC XBRL | +65.9% | +28.1% | INVA higher |
| Gross margin FY2025, SEC XBRL | +74.8% | n/a | |
| Operating margin FY2025, SEC XBRL | +39.8% | n/a | |
| ROE FY2025, SEC XBRL | +23.1% | +34.7% | MRK higher |
| ROA FY2025, SEC XBRL | +16.6% | +13.3% | INVA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.21 | 1.29 | INVA lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +14.7% | +1.3% | INVA higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +3.1% | INVA higher |
| Dividend yield as of 2026-09-03 | n/a | +2.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 19 | MRK higher |
| Beta as of 2026-09-02 | 0.14 | 0.29 | |
| 1-year return as of 2026-10-20 close | +23.6% | +71.8% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.